339 related articles for article (PubMed ID: 27923357)
1. Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany.
Hofheinz R; Clouth J; Borchardt-Wagner J; Wagner U; Weidling E; Jen MH; Brück P
BMC Cancer; 2016 Dec; 16(1):937. PubMed ID: 27923357
[TBL] [Abstract][Full Text] [Related]
2. Patient preferences for outcomes of depression treatment in Germany: a choice-based conjoint analysis study.
Zimmermann TM; Clouth J; Elosge M; Heurich M; Schneider E; Wilhelm S; Wolfrath A
J Affect Disord; 2013 Jun; 148(2-3):210-9. PubMed ID: 23290792
[TBL] [Abstract][Full Text] [Related]
3. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
4. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
Cohen DJ; Newman E; Iqbal S; Chang RY; Potmesil M; Ryan T; Donahue B; Chandra A; Liu M; Utate M; Hiotis S; Pachter LH; Hochster H; Muggia F
Ann Surg Oncol; 2012 Feb; 19(2):478-85. PubMed ID: 21769462
[TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
[TBL] [Abstract][Full Text] [Related]
6. Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis.
Bridges JF; Mohamed AF; Finnern HW; Woehl A; Hauber AB
Lung Cancer; 2012 Jul; 77(1):224-31. PubMed ID: 22369719
[TBL] [Abstract][Full Text] [Related]
7. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
[TBL] [Abstract][Full Text] [Related]
8. Palliative resection for advanced gastric and junctional adenocarcinoma: which patients will benefit from surgery?
Mariette C; Bruyère E; Messager M; Pichot-Delahaye V; Paye F; Dumont F; Brachet D; Piessen G;
Ann Surg Oncol; 2013 Apr; 20(4):1240-9. PubMed ID: 23064779
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of a hierarchical Bayes method for utility estimation in a choice-based conjoint analysis of prescription benefit plans including medication therapy management services.
Wellman GS; Vidican C
Res Social Adm Pharm; 2008 Sep; 4(3):218-30. PubMed ID: 18794033
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
Scott LC; Yao JC; Benson AB; Thomas AL; Falk S; Mena RR; Picus J; Wright J; Mulcahy MF; Ajani JA; Evans TR
Cancer Chemother Pharmacol; 2009 Jan; 63(2):363-70. PubMed ID: 18398613
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
Newman E; Potmesil M; Ryan T; Marcus S; Hiotis S; Yee H; Norwood B; Wendell M; Muggia F; Hochster H
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S97-100. PubMed ID: 16399443
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
13. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
14. Staging of adenocarcinoma of the gastroesophageal junction.
Parry K; Haverkamp L; Bruijnen RC; Siersema PD; Offerhaus GJ; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2016 Mar; 42(3):400-6. PubMed ID: 26777127
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
16. A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programs.
Atkinson-Clark E; Charokopou M; Van Osselaer N; Hiligsmann M
Epilepsy Behav; 2018 Feb; 79():58-67. PubMed ID: 29248866
[TBL] [Abstract][Full Text] [Related]
17. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
Wilson L; Loucks A; Bui C; Gipson G; Zhong L; Schwartzburg A; Crabtree E; Goodin D; Waubant E; McCulloch C
J Neurol Sci; 2014 Sep; 344(1-2):80-7. PubMed ID: 25037284
[TBL] [Abstract][Full Text] [Related]
18. Clinical profile of carcinoma stomach at a tertiary care hospital in south India.
Sambasivaiah K; Ibrarullah M; Reddy MK; Reddy PV; Wagholikar G; Jaiman S; Reddy DG; Sarma KV; Hegde GN
Trop Gastroenterol; 2004; 25(1):21-6. PubMed ID: 15303466
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
Uncu D; Ozdemir NY; Aksoy S; Abali H; Oksuzoglu BC; Budakoglu B; Yildiz R; Aslan N; Zengin N
Asian Pac J Cancer Prev; 2010; 11(6):1493-7. PubMed ID: 21338186
[TBL] [Abstract][Full Text] [Related]
20. Chronic obstructive pulmonary disease (COPD) patients' disease-related preferences : a study using conjoint analysis.
Pisa G; Freytag S; Schandry R
Patient; 2013; 6(2):93-101. PubMed ID: 23526399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
